Varex Imaging (NASDAQ:VREX) Could Be Struggling To Allocate Capital
For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Varex Imaging:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.033 = US$39m ÷ (US$1.3b - US$151m) (Based on the trailing twelve months to January 2025).
Thus, Varex Imaging has an ROCE of 3.3%. Ultimately, that's a low return and it under-performs the Medical Equipment industry average of 10%.
Check out our latest analysis for Varex Imaging
Above you can see how the current ROCE for Varex Imaging compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Varex Imaging for free.
In terms of Varex Imaging's historical ROCE movements, the trend isn't fantastic. To be more specific, ROCE has fallen from 6.2% over the last five years. However it looks like Varex Imaging might be reinvesting for long term growth because while capital employed has increased, the company's sales haven't changed much in the last 12 months. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line.
Bringing it all together, while we're somewhat encouraged by Varex Imaging's reinvestment in its own business, we're aware that returns are shrinking. And investors appear hesitant that the trends will pick up because the stock has fallen 38% in the last five years. Therefore based on the analysis done in this article, we don't think Varex Imaging has the makings of a multi-bagger.
One more thing to note, we've identified 1 warning sign with Varex Imaging and understanding this should be part of your investment process.
While Varex Imaging may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Raffles Medical Group First Half 2025 Earnings: EPS: S$0.017 (vs S$0.017 in 1H 2024)
Raffles Medical Group (SGX:BSL) First Half 2025 Results Key Financial Results Revenue: S$378.4m (up 3.5% from 1H 2024). Net income: S$32.1m (up 4.8% from 1H 2024). Profit margin: 8.5% (up from 8.4% in 1H 2024). The increase in margin was driven by higher revenue. EPS: S$0.017 (in line with 1H 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Raffles Medical Group Earnings Insights Looking ahead, revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Asia. Performance of the market in Singapore. The company's shares are down 4.8% from a week ago. Risk Analysis Before you take the next step you should know about the 1 warning sign for Raffles Medical Group that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Harn Len Corporation Bhd Full Year 2025 Earnings: EPS: RM0.057 (vs RM0.006 loss in FY 2024)
Harn Len Corporation Bhd (KLSE:HARNLEN) Full Year 2025 Results Key Financial Results Revenue: RM283.2m (up 47% from FY 2024). Net income: RM33.4m (up from RM3.58m loss in FY 2024). Profit margin: 12% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. EPS: RM0.057 (up from RM0.006 loss in FY 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period The primary driver behind last 12 months revenue was the Plantation segment contributing a total revenue of RM279.4m (99% of total revenue). Notably, cost of sales worth RM205.6m amounted to 73% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to RM29.5m (67% of total expenses). Explore how HARNLEN's revenue and expenses shape its earnings. Harn Len Corporation Bhd's share price is broadly unchanged from a week ago. Risk Analysis You should always think about risks. Case in point, we've spotted 3 warning signs for Harn Len Corporation Bhd you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
26 minutes ago
- Yahoo
Don't Buy Chemical Industries (Far East) Limited (SGX:C05) For Its Next Dividend Without Doing These Checks
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Chemical Industries (Far East) Limited (SGX:C05) is about to trade ex-dividend in the next 2 days. The ex-dividend date is commonly two business days before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is important as the process of settlement involves at least two full business days. So if you miss that date, you would not show up on the company's books on the record date. Meaning, you will need to purchase Chemical Industries (Far East)'s shares before the 6th of August to receive the dividend, which will be paid on the 18th of August. The company's next dividend payment will be S$0.005 per share, on the back of last year when the company paid a total of S$0.015 to shareholders. Based on the last year's worth of payments, Chemical Industries (Far East) stock has a trailing yield of around 2.8% on the current share price of S$0.535. If you buy this business for its dividend, you should have an idea of whether Chemical Industries (Far East)'s dividend is reliable and sustainable. As a result, readers should always check whether Chemical Industries (Far East) has been able to grow its dividends, or if the dividend might be cut. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Chemical Industries (Far East) reported a loss after tax last year, which means it's paying a dividend despite being unprofitable. While this might be a one-off event, this is unlikely to be sustainable in the long term. With the recent loss, it's important to check if the business generated enough cash to pay its dividend. If cash earnings don't cover the dividend, the company would have to pay dividends out of cash in the bank, or by borrowing money, neither of which is long-term sustainable. It paid out an unsustainably high 220% of its free cash flow as dividends over the past 12 months, which is worrying. Our definition of free cash flow excludes cash generated from asset sales, so since Chemical Industries (Far East) is paying out such a high percentage of its cash flow, it might be worth seeing if it sold assets or had similar events that might have led to such a high dividend payment. Chemical Industries (Far East) does have a large net cash position on the balance sheet, which could fund large dividends for a time, if the company so chose. Still, smart investors know that it is better to assess dividends relative to the cash and profit generated by the business. Paying dividends out of cash on the balance sheet is not long-term sustainable. Check out our latest analysis for Chemical Industries (Far East) Click here to see how much of its profit Chemical Industries (Far East) paid out over the last 12 months. Have Earnings And Dividends Been Growing? Businesses with shrinking earnings are tricky from a dividend perspective. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. Chemical Industries (Far East) reported a loss last year, and the general trend suggests its earnings have also been declining in recent years, making us wonder if the dividend is at risk. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Chemical Industries (Far East)'s dividend payments are broadly unchanged compared to where they were 10 years ago. When earnings are declining yet the dividends are flat, typically the company is either paying out a higher portion of its earnings, or paying out of cash or debt on the balance sheet, neither of which is ideal. Remember, you can always get a snapshot of Chemical Industries (Far East)'s financial health, by checking our visualisation of its financial health, here. The Bottom Line Is Chemical Industries (Far East) an attractive dividend stock, or better left on the shelf? We're a bit uncomfortable with it paying a dividend while being loss-making, especially given that the dividend was not well covered by free cash flow. It's not an attractive combination from a dividend perspective, and we're inclined to pass on this one for the time being. Having said that, if you're looking at this stock without much concern for the dividend, you should still be familiar of the risks involved with Chemical Industries (Far East). To that end, you should learn about the 4 warning signs we've spotted with Chemical Industries (Far East) (including 3 which are concerning). A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data